Litcius/Paper detail

Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy

Parvin Zamani, Jamshid Gholizadeh Navashenaq, Manouchehr Teymouri, Maryam Karimi, Mohammad Mashreghi, Mahmoud Reza Jaafari

2020Life Sciences40 citationsDOI

Topics & Concepts

MedicineDoxorubicinImmunotherapyCancer researchMyeloid-derived Suppressor CellFOXP3CancerImmune systemCD8ChemotherapyPharmacologyImmunologyInternal medicineSuppressorImmune cells in cancerNanoplatforms for cancer theranosticsImmune Response and Inflammation
Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy | Litcius